Skip to main content

Table 2 Studies excluded for not having met the eligibility criteria

From: Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews

Study excluded

Exclusion code

HÄUSER W, WOLFE F, TÖLLE T, ÜÇEYLER N, SOMMER C. The Role of Antidepressants in the Management of Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis. CNS Drugs. 2012 Apr; 26 (4):297–307.

4

CHOY E, MARSHALL D, GABRIEL ZL, MITCHELL SA, GYLEE E, DAKIN HA. A Systematic Review and Mixed Treatment Comparison of the Efficacy of Pharmacological Treatments for Fibromyalgia. Seminars in Arthritis and Rheumatism. 2011 Dec; 41 (3):335–345.e6.

4

SULTAN A, GASKELL H, DERRY S, MOORE RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. 2008 Dec; 8 (1):29.

2

  1. a) Complete articles considered for inclusion, but excluded for not having met the criteria. Exclusion codes: 1 = ineligible outcome, 2 = ineligible intervention, 3 = ineligible population, 4 = ineligible methodology.
  2. b) The other two papers were old versions of the study of Sommer et al., (2017).
Back to article page

Advances in Rheumatology

ISSN: 2523-3106